Your browser doesn't support javascript.
loading
Transcatheter tricuspid valve replacement for functional tricuspid regurgitation after left-sided valve surgery: A single-center experience.
Wang, Yiwei; Zhai, Mengen; Mao, Yu; Yang, Tingting; Zhu, Guangyu; Liu, Yang; Yang, Jian.
Afiliación
  • Wang Y; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Zhai M; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Mao Y; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Yang T; School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an, China.
  • Zhu G; School of Energy and Power Engineering, Xi'an Jiaotong University, Xi'an, China.
  • Liu Y; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Yang J; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Catheter Cardiovasc Interv ; 103(4): 626-636, 2024 03.
Article en En | MEDLINE | ID: mdl-38353507
ABSTRACT

BACKGROUND:

Functional tricuspid regurgitation (FTR) following left-sided valve surgery (LSVS) is of clinical significance due to its high recurrence and mortality rates. Transcatheter therapy presents a potential solution to address this issue.

AIMS:

The study aimed to assess the safety and efficacy of transcatheter tricuspid valve replacement using the Lux-Valve system in a single center for patients with FTR after LSVS.

METHODS:

From June 2020 to April 2023, 20 patients with symptomatic severe FTR after LSVS were referred to our center. A multidisciplinary cardiac team evaluated these patients for suitability for transcatheter tricuspid valve replacement with Lux-Valve systems. Primary efficacy and safety endpoints were immediate postoperative tricuspid regurgitation severity ≤ moderate and major adverse events during follow-up.

RESULTS:

Twenty patients (average age 65.7 ± 7.4 years; 65.0% women) successfully underwent Lux-Valve system implantation after LSVS. All patients achieved ≤ moderate tricuspid regurgitation immediately after the procedure. Only one patient (5.0%) experienced a procedure-related major adverse event, leading to in-hospital mortality due to pulmonary infection. At the 6-month follow-up, 17 patients (89.5%) improved to New York Heart Association functional class I to II (p < 0.001). The overall Kansas City Cardiomyopathy Questionnaire score significantly improved (35.9 ± 6.7 points to 58.9 ± 5.8 points, p < 0.001).

CONCLUSION:

The Lux-Valve system was found to be safe and effective for treating FTR after LSVS. It resulted in positive early outcomes, including a significant reduction in FTR, improved functional status, and enhanced quality of life, especially in high-risk patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia de la Válvula Tricúspide / Implantación de Prótesis de Válvulas Cardíacas Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Catheter Cardiovasc Interv Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia de la Válvula Tricúspide / Implantación de Prótesis de Válvulas Cardíacas Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Catheter Cardiovasc Interv Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos